The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | Pre-treatment genomic screening to guide venetoclax-based sequencing in t(11;14) myeloma
Linda Baughn, PhD, Mayo Clinic, Rochester, MN, discusses the implications of recent findings on the genomic drivers of acquired resistance to venetoclax in t(11;14) multiple myeloma (MM), including RAS-pathway mutations, and suggests that additional pre-treatment genomic screening may be beneficial to inform sequencing of venetoclax-based therapy. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I had published a paper earlier this year, again in collaboration with Francesco Maura’s group, as well as other investigators, where we identified RAS pathway mutations are associated with reduced response to venetoclax. So I also have a role in a diagnostics laboratory, and I think it is definitely important that if patients are treated with a BCL2 inhibitor, they may want to consider additional diagnostic sequencing to determine the presence or absence of a RAS pathway mutation...
I had published a paper earlier this year, again in collaboration with Francesco Maura’s group, as well as other investigators, where we identified RAS pathway mutations are associated with reduced response to venetoclax. So I also have a role in a diagnostics laboratory, and I think it is definitely important that if patients are treated with a BCL2 inhibitor, they may want to consider additional diagnostic sequencing to determine the presence or absence of a RAS pathway mutation. So I obviously am in favor if the resources are available to perform whole-genome-type sequencing so that we can identify structural variants, copy number abnormalities, as well as SNVs such as RAS mutations for optimal treatment.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
